Wednesday, July 8, 2026

pharma · COVID-19 · Poliomyelitis

Sinovac Research and

SINOVAC BIOTECH (BANGLADESH) is a pharma organization headquartered in Dhaka, CN. Primary therapeutic focus areas include COVID-19, Poliomyelitis, Influenza, Hand, Foot and Mouth Disease, Varicella. NovaPharmaNews links

Dhaka, CN HQ
2022 Founded
9 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Dhaka, CN
Founded
2022
Employees
9
Programs
115
Drugs
54
Patents
0
Clinical program

SARS-CoV-2 Inactivated Vaccine

Approved · mab · COVID-19

SARS-CoV-2 Inactivated Vaccine for COVID-19 is a Approved program (mab) at Sinovac Research and Development Co., with 2 ClinicalTrials.gov record(s).

Internal code PRO-nCOV-4003

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Sinovac Research and Development Co.,
Phase
Approved
Modality
mab
Indication
COVID-19
Status
active
Trials
2